Fostering open innovation, including joint research agreement with HK inno.N
[by Lee, Young Sung] ProEn Therapeutics, a company specializing in the development of novel anti-cancer drugs, announced on March 4 that it has successfully secured a strategic investment from Kolmar Korea Holdings, a global leader in beauty and biohealth. The specific amount of the investment remains undisclosed, as agreed by both parties.
The investment was made to support the identification of promising companies and to stimulate investment activities. This was achieved through a comprehensive evaluation of technological capabilities, market potential, and the likelihood of future collaboration through an open innovation program jointly organized by Kolmar Korea Holdings and Innopolis Special Zone Business Group. ProEn Therapeutics was selected as a participant in this initiative.
ProEn Therapeutics is a company that demonstrates remarkable competitiveness in antibody functional site development among antibody drug conjugate (ADC) new drug development companies. Recently, this sector has received significant global attention.
The company's 'ArtBodyTM' technology, a proprietary platform, specializes in the development of cancer antigen-specific binding proteins optimized for the company's ADCs. This technology promises to significantly reduce the toxicity typically associated with existing ADCs, particularly to normal cells and tissues. By maximizing the selective binding characteristics of cancer cells, ProEn Therapeutics aims to overcome this limitation.
Kolmar Korea Holdings is actively engaged in promoting open innovation collaboration, as exemplified by the co-development projects of ProEn Therapeutics and HK inno.N. As part of this strategic investment, the companies have prioritized the co-development of a novel CAR-T drug targeting solid tumors.
"With this strategic investment and joint research agreement, we expect to identify competitive drug candidates and accelerate our research and development efforts by leveraging the synergies between the technologies owned by both companies," said Lee Il-han, CEO of ProEn Therapeutics.
THEBIO
Fostering open innovation, including joint research agreement with HK inno.N
[by Lee, Young Sung] ProEn Therapeutics, a company specializing in the development of novel anti-cancer drugs, announced on March 4 that it has successfully secured a strategic investment from Kolmar Korea Holdings, a global leader in beauty and biohealth. The specific amount of the investment remains undisclosed, as agreed by both parties.
The investment was made to support the identification of promising companies and to stimulate investment activities. This was achieved through a comprehensive evaluation of technological capabilities, market potential, and the likelihood of future collaboration through an open innovation program jointly organized by Kolmar Korea Holdings and Innopolis Special Zone Business Group. ProEn Therapeutics was selected as a participant in this initiative.
ProEn Therapeutics is a company that demonstrates remarkable competitiveness in antibody functional site development among antibody drug conjugate (ADC) new drug development companies. Recently, this sector has received significant global attention.
The company's 'ArtBodyTM' technology, a proprietary platform, specializes in the development of cancer antigen-specific binding proteins optimized for the company's ADCs. This technology promises to significantly reduce the toxicity typically associated with existing ADCs, particularly to normal cells and tissues. By maximizing the selective binding characteristics of cancer cells, ProEn Therapeutics aims to overcome this limitation.
Kolmar Korea Holdings is actively engaged in promoting open innovation collaboration, as exemplified by the co-development projects of ProEn Therapeutics and HK inno.N. As part of this strategic investment, the companies have prioritized the co-development of a novel CAR-T drug targeting solid tumors.
"With this strategic investment and joint research agreement, we expect to identify competitive drug candidates and accelerate our research and development efforts by leveraging the synergies between the technologies owned by both companies," said Lee Il-han, CEO of ProEn Therapeutics.